Novo Nordisk's market value is the price at which a share of Novo Nordisk trades on a public exchange. It measures the collective expectations of Novo Nordisk AS investors about its performance. Novo Nordisk is trading at 48.75 as of the 11th of February 2026. This is a 1.55 percent down since the beginning of the trading day. The stock's lowest day price was 48.65. With this module, you can estimate the performance of a buy and hold strategy of Novo Nordisk AS and determine expected loss or profit from investing in Novo Nordisk over a given investment horizon. Check out Novo Nordisk Correlation, Novo Nordisk Volatility and Novo Nordisk Performance module to complement your research on Novo Nordisk.
It's important to distinguish between Novo Nordisk's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Novo Nordisk should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Novo Nordisk's market price signifies the transaction level at which participants voluntarily complete trades.
Novo Nordisk 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Novo Nordisk's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Novo Nordisk.
0.00
11/13/2025
No Change 0.00
0.0
In 3 months and 1 day
02/11/2026
0.00
If you would invest 0.00 in Novo Nordisk on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Novo Nordisk AS or generate 0.0% return on investment in Novo Nordisk over 90 days. Novo Nordisk is related to or competes with Novartis, Sartorius Stedim, CSL, Roche Holding, Roche Holding, AstraZeneca PLC, and Fresenius. Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutica... More
Novo Nordisk Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Novo Nordisk's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Novo Nordisk AS upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Novo Nordisk's standard deviation. In reality, there are many statistical measures that can use Novo Nordisk historical prices to predict the future Novo Nordisk's volatility.
At this point, Novo Nordisk is very steady. Novo Nordisk AS has Sharpe Ratio of 0.0262, which conveys that the firm had a 0.0262 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Novo Nordisk, which you can use to evaluate the volatility of the firm. Please verify Novo Nordisk's Mean Deviation of 2.95, downside deviation of 4.2, and Risk Adjusted Performance of 0.0276 to check out if the risk estimate we provide is consistent with the expected return of 0.11%. Novo Nordisk has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.51, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novo Nordisk will likely underperform. Novo Nordisk AS right now secures a risk of 4.2%. Please verify Novo Nordisk AS skewness, and the relationship between the potential upside and rate of daily change , to decide if Novo Nordisk AS will be following its current price movements.
Auto-correlation
-0.31
Poor reverse predictability
Novo Nordisk AS has poor reverse predictability. Overlapping area represents the amount of predictability between Novo Nordisk time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Novo Nordisk AS price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Novo Nordisk price fluctuation can be explain by its past prices.
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Novo Nordisk technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.
A focus of Novo Nordisk technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Novo Nordisk trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...